

*Functional Analysis of ANKRD11 and FBXO31:
Two Candidate Tumour Suppressor Genes from the 16q24.3
Breast Cancer Loss of Heterozygosity Region*

Paul Matthew Neilsen B.Sc. B.Biomed.Sc. (Hon)

Thesis submitted for the Degree of Doctor of Philosophy

Breast Cancer Genetics Group
Faculty of Health Sciences,
School of Medicine, Discipline of Medicine,
University of Adelaide, South Australia.
Hanson Institute, Adelaide, South Australia.

January 2008

This thesis is dedicated to my brother;

*Although you are no longer with us, your undying
determination and passion for life remains with us all.*

*You have always be my guiding light in times of dark,
my guardian angel in the presence of evil.*

*I know you will always be with me, and together
we will walk, hand in hand, along the road towards a cure.*

Table of Contents

ABSTRACT	VII
DECLARATION	IX
LIST OF PUBLICATIONS	X
ABBREVIATIONS	XI
ACKNOWLEDGEMENTS	XV
CHAPTER 1: INTRODUCTION	1
1.1 – Cancer: a genetic disease	1
1.1.1 – Oncogenes and proto-oncogenes	1
1.1.2 – Tumour suppressor genes	2
1.1.2.1 – Inactivation of tumour suppressor genes	2
1.1.2.2 – Retinoblastoma as a model for Knudson’s “two-hit” hypothesis	7
1.1.2.3 – Epigenetic silencing of tumour suppressor genes	8
1.1.2.4 – Haploinsufficient tumour suppressor genes	9
1.2 – Breast cancer	11
1.2.1 – Estrogens and breast cancer	12
1.2.2 – Molecular basis of breast tumorigenesis	12
1.2.2.1 – Breast cancer oncogenes: ERBB2 / HER2	13
1.2.2.2 – Breast cancer oncogenes: CCND1	14
1.2.2.3 – Breast cancer oncogenes: MYC	15
1.2.2.4 – Breast Cancer Tumour Suppressor Genes: TP53	15
1.2.2.5 – Breast Cancer Tumour Suppressor Genes: BRCA1, BRCA2 and BARD1	17
1.3 – Identification of breast cancer tumour suppressor genes	19
1.3.1 – Identification of the smallest region of overlap for 16q LOH in breast cancer	19
1.3.1.1 – CDH1: the 16q22.1 breast cancer tumour suppressor gene	20
1.3.1.2 - Identification of the 16q24.3 breast cancer tumour suppressor gene(s)	21
1.3.1.2.1 - FBXO31 (F-box protein 31)	22
1.3.1.2.2 - CBFA2T3 (Core-binding factor, runt domain, alpha subunit 2; translocated to 3)	22
1.3.1.2.3 – CYBA (Cytochrome b-245, alpha polypeptide)	23
1.3.1.3 - Does 16q24.3 harbour multiple breast cancer tumour suppressor genes?	24
1.3.1.3.1 - ANKRD11 (Ankyrin repeat domain 11)	25
CHAPTER 2: GENERAL MATERIALS AND METHODS	26
2.1 - Cell lines and transient transfections	26
2.2 – Antibodies	27
2.3 - Immunofluorescence	28
2.4 - Reverse transcription real time-PCR (RT-PCR)	28
2.5 - Western blot analysis	29
	III

2.6 – Oligo-primers and DNA constructs	30
2.7 – DNA sequence analysis	30
2.8 – In silico analysis	30
2.9 – Cell Culture Synchronisation	31
CHAPTER 3: FUNCTIONAL CHARACTERISATION OF ANKRD11	43
3.1 – Identification of ANKRD11 as a novel p53 coactivator involved in the rescue of mutant p53	43
3.1.1 – Prelude	43
3.1.1.1 – Selection of ANKRD11 as a candidate 16q24.3 breast cancer tumour suppressor gene	43
3.1.1.2 – Characterisation of the ANKRD11 gene	43
3.1.2 – Introduction	45
3.1.3 – Materials and Methods	48
3.1.3.1 – Cell lines and antibodies	48
3.1.3.2 – Plasmids	48
3.1.3.3 – Immunofluorescence	48
3.1.3.4 – Glycerol Gradient Fractionation	48
3.1.3.5 – In silico analysis	49
3.1.3.6 – Co-immunoprecipitation assays	49
3.1.3.7 – In vitro binding assays	49
3.1.3.8 – Promoter binding assays	50
3.1.3.9 – Reporter assays	50
3.1.3.10 – Reverse transcription real time-PCR (RT-PCR)	51
3.1.3.11 – Cell-based assays	51
3.1.3.12 – Yeast two-hybrid screen	51
3.1.3.13 – β -Galactosidase assay	52
3.1.3.14 – Statement of work	52
3.1.4 – Results	53
3.1.4.1 – ANKRD11 associates with p53, p14 ^{ARF} and PML in extranucleolar inclusions	53
3.1.4.2 – ANKRD11 interacts with p53 in vivo and in vitro through the ankyrin repeat domain	57
3.1.4.3 – ANKRD11 enhances p53-mediated transcription	61
3.1.4.4 – ANKRD11 expression in breast cell lines	61
3.1.4.5 – Restoration of ANKRD11 enhances p53-dependent expression of p21 ^{waf1}	64
3.1.4.6 – Restoration of ANKRD11 expression suppresses the growth characteristics of breast cancer cell lines	65
3.1.4.7 – Silencing of ANKRD11 reduces p53 transcriptional activity	68
3.1.4.8 – ANKRD11 associates with hADA3 and P/CAF and increases p53 acetylation	68
3.1.4.9 – ANKRD11 enhances DNA-binding of the p53 ^{R273H} mutant	69
3.1.4.10 – ANKRD11 is a p53 target gene	72
3.1.5 – Discussion	75
3.2 – Identification of a putative p53-interaction motif located within the ANK domain	80
3.2.1 – Prelude	80
3.2.2 – Introduction	80
3.2.2.1 – The structural architecture of the ANK domain	80
3.2.2.2 – Ankyrin proteins: a novel family of p53 regulators?	81
3.2.2.2.1 – BARD1: a regulator of the apoptotic function of p53	83
3.2.2.2.2 – 53bp2: a regulator of the transcriptional function of p53	83

3.2.2.2.3 – IκBα: a regulator of p53 localisation	84
3.2.2.3 – The ANK domain is frequently involved in p53 interaction	84
3.2.3 – Materials and Methods	85
3.2.3.1 – In silico analysis	85
3.2.4 – Results	86
3.2.4.1 – Homology between ANK domains of ANKRD11, BARD1, IκBα and 53bp2	86
3.2.4.2 – Identification of a putative ANK-based p53-interaction motif	86
3.2.5 – Discussion	89
3.3 – Characterisation of a role for ANKRD11 as a putative cell cycle checkpoint protein	92
3.3.1 – Introduction	92
3.3.1.1 – The cell cycle	92
3.3.1.2 – Regulation of the cell cycle	92
3.3.1.3 – The Ubiquitin Proteolytic Pathway	93
3.3.1.3.1 – Polyubiquitination	93
3.3.1.3.2 – E3 ubiquitin ligases	95
3.3.1.3.2.1 – E3 ubiquitin ligases: the SCF complex	96
3.3.1.3.2.2 – E3 ubiquitin ligases: the APC/C complex	96
3.3.1.3.3 – Cell cycle checkpoints	101
3.3.1.3.3.1 – The G ₁ /S phase checkpoint	101
3.3.1.3.3.2 – The intra-S phase checkpoint	102
3.3.1.3.3.3 – The G ₂ /M phase checkpoint	103
3.3.1.3.3.4 – The spindle assembly checkpoint	103
3.3.1.3.4 – Aberrant regulation of cell cycle proteins and checkpoints during breast tumorigenesis	104
3.3.2 – Materials and Methods	105
3.3.2.1 – Cell lines and antibodies	105
3.3.2.2 – Plasmids	105
3.3.2.3 – Immunofluorescence	105
3.3.2.4 – Cell culture synchronization	105
3.3.2.5 – Subcellular biochemical fractionation	105
3.3.3 – Results	107
3.3.3.1 – ANKRD11 exhibits partial localisation with PML bodies	107
3.3.3.2 – ANKRD11 localises with PML isoforms	109
3.3.3.3 – ANKRD11 associates with chromatin during mitosis and is rapidly degraded during mitotic progression	109
3.3.3.4 – ANKRD11 associates with histone H2A	115
3.3.3.5 – ANKRD11 is a cell cycle regulated protein	117
3.3.3.6 – ANKRD11 translocates to the nucleolus following proteasomal inhibition	118
3.3.3.7 – ANKRD11 contains a consensus destruction box and multiple PEST sequences	119
3.3.4 – Discussion	121
3.3.4.1 – The dynamic regulation of ANKRD11 during mitosis	121
3.3.4.2 – Association of ANKRD11 with chromatin-rich regions	122
3.3.4.2.1 – Is ANKRD11 recruited to chromatin via interaction with nucleosomes?	122
3.3.4.2.2 – ANKRD11-histone association: direct or indirect?	123
3.3.4.3 – Proteasomal-mediated degradation of ANKRD11	124
3.4 – Investigation into a role for ANKRD11 in the modulation of estrogen receptor activity	126
3.4.1 – Prelude	126

3.4.2 – Introduction	126
3.4.2.1 – Steroid nuclear receptors and transcriptional regulation	126
3.4.2.2 – The p160 family of steroid receptor coactivators	127
3.4.2.2.1 – Structural and function domains of the SRC family – the bHLH-PAS domain	127
3.4.2.2.2 – Structural and function domains of the SRC family – the LXXLL motif	127
3.4.2.2.3 – Structural and function domains of the SRC family – the AD domain	128
3.4.2.3 – AIB1 and breast cancer	129
3.4.2.4 – ANKRD11: a novel antagonist of the p160 coactivators	129
3.4.3 – Materials and Methods	131
3.4.3.1 – Cell lines and antibodies	131
3.4.3.2 – Plasmids	131
3.4.3.3 – Estrogen receptor transactivation assays	131
3.4.3.4 – Co-immunoprecipitation assays	131
3.4.4 – Results	132
3.4.4.1 – ANKRD11 enhances estrogen receptor-mediated transcriptional activity	132
3.4.4.2 – ANKRD11 interacts with ERBP in vivo via the amino-terminal ankyrin region	136
3.4.5 – Discussion	138
CHAPTER 4: FBXO31 IS THE CHROMOSOME 16Q24.3 SENESCENCE GENE, A CANDIDATE BREAST TUMOUR SUPPRESSOR, AND A COMPONENT OF AN SCF COMPLEX	142
4.1 - Prelude	142
4.2 – Introduction	142
4.3 – Materials and Methods	144
4.3.1 - Cell lines and antibodies	144
4.3.2 – Plasmids	144
4.3.3 – Human tissues	144
4.3.4 – Northern blot	144
4.3.5 – Real-time reverse transcription-PCR	145
4.3.6 – Cell-based assays	145
4.3.7 – Cell synchronization	146
4.3.8 – Cell cycle analysis	146
4.3.9 – Western blot analysis	146
4.4 – Results	149
4.4.1 – Analysis of 16q24.3 senescence region	149
4.4.2 – Northern blot and in silico analysis	153
4.4.3 – Ectopic expression of FBXO31 induces cellular senescence in MCF-7	153
4.4.4 – Alteration of FBXO31 expression affects growth of breast cell lines	156
4.4.5 – FBXO31 expression and mutation screening	159
4.4.6 – FBXO31 is cell cycle regulated	161
4.4.7 – FBXO31 exists as a component of SCF ^{FBXO31} complex	164
4.5 – Discussion	167
REFERENCES	172

Erratum

Erratum to the doctoral thesis entitled “Functional Analysis of *ANKRD11* and *FBXO31*: Two Candidate Tumour Suppressor Genes From the 16q24.3 Breast Cancer Loss of Heterozygosity Region” by Paul Neilsen.

Abstract – Page VII – Second Paragraph – Line 3:

Replace the comma with “which”

Introduction – Page 2 – Third Paragraph – Line 7:

Change “single nucleotide polymorphism” to “tumour-restricted single nucleotide polymorphism”

Chapter 3 – Page 54 – First Paragraph – Line 4:

Insert the sentence “Transiently-expressed ANKRD11 protein accumulated in nuclear foci that were more numerous and larger in size than that of endogenous ANKRD11.”

Abstract

Loss of heterozygosity (LOH) on the long arm of chromosome 16 is frequently observed during the onset of breast cancer. Our laboratory has recently identified both *ANKRD11* and *FBXO31* as candidate tumour suppressor genes in the chromosome band 16q24.3, which is the smallest region of overlap for breast cancer LOH. This thesis focuses on the functional analysis of these two novel genes and implicates a role for them as breast cancer tumour suppressors.

ANKRD11: a novel p53 coactivator involved in the rescue of mutant p53

The ability of p53 to act as a transcription factor is critical for its function as a tumour suppressor. Ankyrin repeat domain 11 (ANKRD11) was found to be a novel p53-interacting protein which enhanced the transcriptional activity of p53. ANKRD11 expression in breast cancer cell lines was shown to be down-regulated when compared to ANKRD11 expression in finite life-span HMECs and non-malignant immortalized breast epithelial cells. Restoration of ANKRD11 expression in MCF-7 (p53 wild-type) and MDA-MB-468 (p53^{R273H} mutant) cells suppressed the oncogenic properties of these breast cancer cell lines through enhancement of p21^{waf1} expression. ShRNA-mediated silencing of ANKRD11 reduced the ability of p53 to activate p21^{waf1} expression in response to DNA damage. ANKRD11 was shown to associate with the p53 acetyltransferase, P/CAF, and exogenous ANKRD11 expression increased the levels of acetylated p53. Exogenous ANKRD11 expression enhanced the DNA-binding properties of the p53^{R273H} mutant to the *CDKN1A* promoter, implicating a role for ANKRD11 in the restoration of mutant p53^{R273H} function. These findings demonstrate a role for ANKRD11 as a p53 coactivator and illustrate the potential of ANKRD11 in the restoration of mutant p53^{R273H} function.

ANKRD11 has roles beyond that of p53 coactivation. This thesis also presents preliminary findings to suggest that ANKRD11 may be involved in the regulation of eukaryotic cell division. Furthermore, ANKRD11 was shown to function as an estrogen receptor coactivator. Taken together, these findings suggest that ANKRD11 is a multi-functional cancer-related protein.

FBXO31: the 16q24.3 senescence gene

A BAC located in the 16q24.3 breast cancer loss of heterozygosity region was previously shown to restore cellular senescence when transferred into breast tumour cell lines. We have shown that *FBXO31*, although located just distal to this BAC, can induce cellular senescence in the breast cancer cell line MCF-7 and is the likely candidate senescence gene. Exogenous *FBXO31* expression inhibited the oncogenic properties of the MCF-7 breast cancer cell line. In addition, compared to the relative expression in normal breast, levels of *FBXO31* were down-regulated in breast tumour cell lines and primary tumours. *FBXO31* protein levels were cell cycle regulated, with maximal expression from late G₂ to early G₁ phase. Ectopic expression of *FBXO31* in the breast cancer cell line MDA-MB-468 resulted in the accumulation of cells at the G₁ phase of the cell cycle. *FBXO31* was also shown to be a component of a SCF ubiquitination complex. We propose that *FBXO31* functions as a tumour suppressor by generating SCF^{*FBXO31*} complexes that target particular substrates, critical for the normal execution of the cell cycle, for ubiquitination and subsequent degradation.

Declaration

This thesis contains no material which has been accepted for the award of any other degree or diploma in any university and that, to the best of my knowledge and belief, the thesis contains no material previously published or written by another person, except where due reference is made in the text of the thesis.

I consent to the thesis being made available for photocopying and loan if accepted for the award of the degree.

Signed:

Date:

List of Publications

Kumar R, **Neilsen PM**, Crawford J, McKirdy R, Lee J, Powell JA, Saif Z, Martin JM, Lombaerts M, Cornelisse CJ, Cleton-Jansen A-M, Callen DF. (2005). FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. *Cancer Res* 65:11304-11313. *Impact Factor* = 7.7

Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF. (2007). Identification of ANKRD11 as a novel p53 coactivator involved in the rescue of mutant p53. *J Cell Sci*. Submitted November 2007. *Impact Factor* = 6.4

Kumar R, Cheney KM, McKirdy R, **Neilsen PM**, Schulz RB, Lee J, Cohen J, Booker GW, Callen DF (2007). CBFA2T3-ZNF652 corepressor complex regulates transcription of the E-box gene *HEB*. *J Biol Chem*. Submitted November 2007. *Impact Factor* = 5.8

Abbreviations

α -X – Anti-X antibody (e.g. α -FLAG)

ACTR – Acetyltransferase

AD – Activator domain

ADH – Atypical ductal hyperplasia

AIB1 – Amplified in breast cancer 1

AML – Acute myeloid leukaemia

ANK domain – Ankyrin repeat domain

ANOVA – Analysis of variance

AR – Androgen receptor

ASPP – Ankyrin-repeats, SH3 domain and proline-rich region containing protein

ATCC – American type culture collection

BAC – Bacterial artificial chromosome

bHLH – Basic helix-loop-helix

CBP – CREB binding protein

Cdk – Cyclin dependent kinase

cDNA – Complementary DNA

ChIP – Chromatin immunoprecipitation

CKI – Cyclin dependent kinase inhibitor

CREB – cAMP response element-binding

DAPI – 4',6-diamidino-2-phenylindole

DBD – DNA-binding domain

D-box – Destruction Box

DCIS – Ductal carcinoma *in situ*

DNA – Deoxyribonucleic acid

DSB – Double-strand breaks

DTT – Dithiothiol

E1 – Ubiquitin activating enzyme

E2 – Ubiquitin conjugating enzyme

E3 – Ubiquitin ligase

EBI – European Bioinformatics Institute

EBV – Epstein-Barr virus

EGF – Epidermal growth factor

EGFP – Enhanced green fluorescent protein

ER – Estrogen receptor

ER α – Estrogen receptor alpha

ER β – Estrogen receptor beta

ERE – Estrogen response element

FCS – Fetal calf serum

GFP – Green fluorescent protein

GR – Glucocorticoid receptor

GRIP-1 – Glucocorticoid receptor interacting protein 1

GST – Glutathione S-transferase

H2A – Histone 2A

HA – Hemagglutinin

HAT – Histone acetyltransferase

HDAC – Histone deacetyltransferase

HMEC – Human mammary epithelial cell

IDC – Invasive ductal carcinoma

IF – Immunofluorescence

IHC – Immunohistochemistry

ILC – Invasive lobular carcinoma

IP – Immunoprecipitation

KLH – Keyhole limpet hemocyanin

LBD – Ligand-binding domain

LCIS – Lobular carcinoma *in situ*

LOH – Loss of heterozygosity

LRES – Long-range epigenetic silencing

MAPK – Microtubule-associated protein kinase

MBP – Maltose-binding protein

MEK2 – MAPK kinase 2

miRNA – Micro RNA

MMC – Mitomycin C

MR – Mineralocorticoid receptor

mRNA – Messenger RNA

NCBI – National center for biotechnology information

NCoA – Nuclear receptor coactivator

NLS – Nuclear localisation signal

NPC – Nasopharyngeal carcinoma

ONPG – *O*-nitrophenyl- β -galactopyranoside

ORC2 – Origin recognition complex subunit 2

p53-RE – p53 response element

p/CIP – p300/CBP interacting protein

PAC – P1 artificial chromosome

PAS domain – Per-Arnt-Sim domain

PCR – Polymerase chain reaction

PEST sequence – Proline, glutamic acid, serine and threonine rich sequence

PR – Progesterone receptor

RAC3 – Receptor-associated coactivator 3

RD – Repressor domain

Real-time RT-PCR – Reverse transcription real time-PCR

RNA – Ribonucleic acid

ROS – Reactive oxygen species

RT – Room temperature

SAC – Spindle assembly checkpoint

SAHA – Suberoylanilide hydroxamic acid

SDS – Sodium dodecylsulphate

SDS-PAGE – SDS Polyacrylamide gel electrophoresis

SEM – Standard error of the mean

SERM – Selective estrogen receptor modulator

shRNA – Short hairpin RNA

siRNA – Small interfering RNA

SNP – Single nucleotide polymorphism

SRC – Steroid receptor coactivator

SRO – Smallest region of overlap

SSCP – Single-strand conformation polymorphism

TIF2 – Transcriptional intermediary factor 2

TK – Thymidine kinase

TRAM-1 – Thyroid hormone receptor activator molecule 1

Ub – Ubiquitin

UDH – Usual ductal hyperplasia

WB – Western blot

Y2H – Yeast-2-hybrid

Acknowledgements

As I reflect on the work that has culminated in this thesis, I wish to acknowledge the contributions made by the following people.

Firstly, I sincerely wish to thank my supervisors, Associate Professor David Callen and Dr Raman Sharma. Without their daily guidance, encouragement and support, I certainly would have struggled throughout my candidature. Their generosity and friendship are invaluable to me and will be remembered throughout the rest of my career. One could not have asked for better mentors.

I would like to thank the dynamic team at the Breast Cancer Genetics Laboratory. The friendships that I have developed over the years certainly made my candidature most enjoyable. I also wish to thank those work colleagues who have made direct contributions to my PhD research, including Associate Professor David Callen, Dr Raman Sharma, Dr Kelly Cheney, Renée Schulz, Jacqueline Cawrse, Jaclyn Lee, Zarqa Saif and Professor J. Don Chen. I would also like to thank Dr Ghafar Sarvestani for his expertise on the confocal microscope.

Finally, I sincerely wish to thank my family. The emotional and financial support has provided me with the necessary foundations to build my PhD upon, and without it I surely would not have made it through my candidature. I thank you from the bottom of my heart.